REGENXBIO Inc. has grown revenue 22% a year over three years and 1.6% a year over five. Revenue growth, 3-year annual rate: +22% (Biotechnology median +17%). Revenue growth, 5-year rate: +1.6%, growth has picked up over the last three years. Years of annual history on file: 13, FY2013 to FY2025, as filed.

RGNXREGENXBIO Inc.

Healthcare

$8.08-23% 1Y

$8.08

$5.6552 weeks$15.98

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +12% year on year, but operating margin narrowing (−215.4 points).

1 good, 1 to watch, 1 without data

Revenue trend+12% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +2% a year.

Margin direction−215.4 points operating

Trailing-twelve-month operating margin, -410.8% now against -195.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is RGNX growing?

REGENXBIO Inc. has grown revenue 22% a year over three years and 1.6% a year over five.

+22%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +1.6%
Revenue growth, 5-year rate · +22% over three · growth has picked up over the last three years
Years of annual history on file: 13
Years of annual history on file · FY2013 to FY2025, as filed

Details›